Pathwork picks up $20m for cancer test
This article was originally published in Clinica
Sunnyvale, California-based Pathwork Diagnostics has raised $20m in its second round of financing led by Abingworth. The new capital will be used to support commercialisation of Pathwork's Tissue of Origin test for determining the origin of uncertain tumours. The product was cleared by the FDA in August. The company added that some of the new capital will also go towards new product development.